The results indicated that enzalutamide could only inhibit 22Rv1 tumor growth weakly, mainly due to ARV7 overexpression, while both XR-2 monotherapy and combination therapy suppressed 22Rv1 tumor progression and decreased tumor weight significantly (Supplementary Figure S6A, S7A,B). The gene discussed is DCXR; the disease is neoplasm.